Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
Yu Han, Jianjun Chen, Dezhi Zou, et al.
Neuropsychiatric Disease and Treatment (2016) Vol. Volume 12, pp. 2859-2867
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Inflammation in psychiatric disorders: what comes first?
Moisés Evandro Bauer, Antônio Lúcio Teixeira
Annals of the New York Academy of Sciences (2018) Vol. 1437, Iss. 1, pp. 57-67
Open Access | Times Cited: 410
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 300
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia‐Melo, et al.
European Archives of Psychiatry and Clinical Neuroscience (2020) Vol. 271, Iss. 3, pp. 577-582
Closed Access | Times Cited: 222
The medial habenula and interpeduncular nucleus circuitry is critical in addiction, anxiety, and mood regulation
Ian McLaughlin, John A. Dani, Mariella De Biasi
Journal of Neurochemistry (2017) Vol. 142, Iss. S2, pp. 130-143
Open Access | Times Cited: 197
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 168
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study
Fernanda S. Correia‐Melo, Gustavo C. Leal, Flávia Vieira, et al.
Journal of Affective Disorders (2019) Vol. 264, pp. 527-534
Closed Access | Times Cited: 148
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
Roger S. McIntyre, Isabelle P. Carvalho, Leanna M.W. Lui, et al.
Journal of Affective Disorders (2020) Vol. 276, pp. 576-584
Closed Access | Times Cited: 148
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 126
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Stevan Nikolin, Anthony Rodgers, Andreas Schwaab, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102127-102127
Open Access | Times Cited: 65
Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: A meta-analysis
Shuying Li, Wenqin Zhou, Ping Li, et al.
Journal of Affective Disorders (2024) Vol. 351, pp. 720-728
Open Access | Times Cited: 23
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Jennifer Jones, Camilo F. Mateus, Robert Malcolm, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 103
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Kathryn R. Cullen, Palistha Amatya, Mark G. Roback, et al.
Journal of Child and Adolescent Psychopharmacology (2018) Vol. 28, Iss. 7, pp. 437-444
Open Access | Times Cited: 94
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Jennifer Swainson, Alexander McGirr, Pierre Blier, et al.
The Canadian Journal of Psychiatry (2020) Vol. 66, Iss. 2, pp. 113-125
Open Access | Times Cited: 79
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 40
Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review
Bess M. Kew, Richard Porter, Katie M. Douglas, et al.
BJPsych Open (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 35
Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
Jolien K. E. Veraart, M. van Westenbrugge, J.E. van Wulfften Palthe, et al.
Heliyon (2023) Vol. 9, Iss. 5, pp. e15883-e15883
Open Access | Times Cited: 25
Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 10
Ketamine Treatment for Alcohol Use Disorder: A Systematic Review
Michael Kelson, Justin M Burnett, Amy Matthews, et al.
Cureus (2023)
Open Access | Times Cited: 19
Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial
Ahmad Zolghadriha, Afagh Anjomshoaa, Mohammad Jamshidi, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Brigitte Vanle, William Olcott, Jaime M. Jimenez, et al.
Translational Psychiatry (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
George A. Mashour, Arbi Ben Abdallah, Kane O. Pryor, et al.
British Journal of Anaesthesia (2018) Vol. 121, Iss. 5, pp. 1075-1083
Open Access | Times Cited: 59
Treatment for Substance Use Disorder With Co-Occurring Mental Illness
Muhammad N. Iqbal, Charles J. Levin, Frances R. Levin
FOCUS The Journal of Lifelong Learning in Psychiatry (2019) Vol. 17, Iss. 2, pp. 88-97
Open Access | Times Cited: 50
Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double‐blind, randomized clinical trial
Jiaxin Yao, Tingting Song, Yue Zhang, et al.
Brain and Behavior (2020) Vol. 10, Iss. 9
Open Access | Times Cited: 48
Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials
Wei Zheng, Xiao-Hong Li, Xiaomin Zhu, et al.
Journal of Affective Disorders (2019) Vol. 250, pp. 123-131
Closed Access | Times Cited: 47
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression
Terry Schwartz, Mary Ellen Trunko, David Feifel, et al.
Clinical Case Reports (2021) Vol. 9, Iss. 5
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top